Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...

Eculizumab effectively reduced MG-ADL scores and corticosteroid use in thymoma-associated myasthenia gravis patients by week 12. The monoclonal antibody targets complement protein C5, preventing ...

AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for ...

AstraZeneca’s anti-complement medical therapy, eculizumab receives CDSCO approval: Our Bureau, Bengaluru Friday, January 17, 2025, 10:30 Hrs [IST] AstraZeneca Pharma India recei ...

There is an approved treatment — a therapeutic antibody called eculizumab — but its half-life of only 11.3 days means patients need to endure transfusion every two weeks. In 2018, researchers ...

Recent off-label use of a complement inhibiting drug, eculizumab (CD55 inhibitor) was shown to provide a dramatic benefit in patients with CHAPLE disease with an immediate correction of ...

AstraZeneca Pharma India rose 1.10% to Rs 10,754 after the firm received approval from the Central Drugs Standard Control Organisation (CDSCO) to import pharmaceutical formulations of eculizumab ...

In the U.S., EPYSQLI (eculizumab-aagh) was approved by the U.S. Food and Drug Administration (FDA) as a biosimilar to Soliris ® (eculizumab) in July 2024 for the treatment of patients with paroxysmal ...

Number 4: Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in a phase 3 trial involving postmenopausal women with osteoporosis ...

Patient-reported outcomes were also examined in the phase 3 ALPHA trial of danicopan as an add-on therapy to ravulizumab or eculizumab. Results suggested that the add-on could improve quality of life.